<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002228</url>
  </required_header>
  <id_info>
    <org_study_id>295A</org_study_id>
    <secondary_id>TRI-003</secondary_id>
    <nct_id>NCT00002228</nct_id>
  </id_info>
  <brief_title>A Study of T-20 in HIV-Positive Adults</brief_title>
  <official_title>A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trimeris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive
      adults. T-20 is an anti-HIV drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by
      subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks;
      including a 2-week screening period, followed by 28 days of treatment and 1 week of
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>78</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enfuvirtide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the
             screening visit.

          -  Antibiotics for bacterial infections.

          -  Prophylactic medications for P. carinii pneumonia and for M. avium, including
             azithromycin.

          -  Medications for symptomatic treatment such as antipyretics, analgesics, and
             antiemetics.

        Patients must have:

        HIV-1 seropositive status.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

        Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the
        cervix, and non-disseminated stable Kaposi's sarcoma).

        Concurrent Medication:

        Excluded:

          -  Patients must not be taking any concurrent antiretroviral therapy (for at least 2
             weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen
             which has not changed for at least 6 weeks prior to baseline.

          -  Treatment with any of the following:

          -  immunomodulators, biological response modifiers, chemotherapy that cannot be
             discontinued for the duration of the study, astemizole, terfenadine, cisapride,
             triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30
             days prior to the initial visit.

        Patients with the following prior conditions are excluded:

          -  Evidence of active opportunistic infections, or unexplained temperature greater than
             or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening
             visit.

          -  Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for
             15 days) within 30 days prior to screening visit.

          -  Diagnosis of hemophilia or other clotting disorders.

        Prior Medication:

        Excluded:

        - Prior treatment with an HIV vaccine.

        Prior Treatment:

        Excluded:

        Major organ allograft.

        Risk Behavior:

        Excluded:

        Evidence of substance abuse or addiction that, in the opinion of the investigator, may
        interfere with the patient's ability to comply with the dosing schedule and protocol
        evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Hopkins</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham / 1917 AIDS O/P Cln</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine / Ctr for Research and Education</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900951793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDC Research Initiative</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ / Infect Dis Div / Pasavant Pav 828</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI of New England</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med Ctr / C &amp; D Building</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ North Carolina at Chapel Hill / Dept of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas / Thomas Street Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Injections, Subcutaneous</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>peptide T20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

